Knight Therapeutics (GUD) Set to Announce Earnings on Thursday

Knight Therapeutics (TSE:GUD) is scheduled to post its quarterly earnings results before the market opens on Thursday, August 8th. Analysts expect Knight Therapeutics to post earnings of C$0.03 per share for the quarter.

Knight Therapeutics (TSE:GUD) last announced its earnings results on Thursday, May 9th. The company reported C($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of C$0.02 by C($0.06). The business had revenue of C$86.60 million for the quarter, compared to analyst estimates of C$80.27 million. Knight Therapeutics had a negative return on equity of 2.21% and a negative net margin of 5.25%.

Knight Therapeutics Trading Down 0.4 %

Shares of GUD stock opened at C$5.65 on Friday. The stock has a 50 day simple moving average of C$5.71 and a 200 day simple moving average of C$5.64. Knight Therapeutics has a 1 year low of C$4.35 and a 1 year high of C$6.22. The company has a current ratio of 3.34, a quick ratio of 1.79 and a debt-to-equity ratio of 9.20. The stock has a market cap of C$572.80 million, a P/E ratio of -35.44, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.46.

Analyst Upgrades and Downgrades

Separately, Stifel Nicolaus increased their price target on shares of Knight Therapeutics from C$5.40 to C$5.75 in a research report on Friday, May 10th.

Insider Activity at Knight Therapeutics

In other Knight Therapeutics news, Senior Officer Amal Khouri sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of C$5.80, for a total value of C$116,022.00. In other Knight Therapeutics news, Director Jonathan Ross Goodman bought 5,000 shares of Knight Therapeutics stock in a transaction on Wednesday, June 5th. The shares were purchased at an average cost of C$5.80 per share, with a total value of C$29,000.00. Also, Senior Officer Amal Khouri sold 20,000 shares of the firm’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of C$5.80, for a total transaction of C$116,022.00. In the last three months, insiders have sold 90,000 shares of company stock valued at $526,783. 46.36% of the stock is owned by insiders.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.